Skip to main content
. 2020 May 8;11:2319. doi: 10.1038/s41467-020-16128-5

Fig. 8. Targeting the Btk SH2-KD interface decreases activation of therapy-resistant Btk with mutation on C481.

Fig. 8

a Immunoblot analysis of cell lysates from HEK293 cells transiently co-transfected with indicated Btk C481S constructs and repebodies used to assess Btk pY551 phosphorylation. b Quantification of pY551 shown in a normalized to total Btk (Myc) expression and relative to rNB control. Data are mean ± SD of two biological replicates (n = 3) and P-values were calculated using an unpaired t-test. *P ≤ 0.05. Source data are provided as a Source Data file.